Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA platform to treat or prevent diseases such as cancer. They did not include ...
He also worked on The Journal’s publishing desk; as a writer and editor covering stocks at Barron’s; as an editor of features at MarketWatch; and on product development efforts at The Journal. ...
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
A newly discovered bat coronavirus uses the same cell-surface protein to gain entry into human cells as the Sars-CoV-2 virus ...
Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with the ...
Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...
An epidemiologist said the Franklin County resolution was "based on conspiracy and misinformation against the COVID-19 ...
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic began—proof that health authorities had planned the pandemic in advance.
Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results